|
|||||
|
|
Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial |
|
| Authors: | Ellen M Ginzler Stephen Wax Anand Rajeswaran Samuel Copt Jan Hillson Eleanor Ramos Nora G Singer |
| Affiliation: | (1) SUNY Downstate Medical Center, 450 Clarkson Avenue, Box 42, Brooklyn, NY 11203, USA;(2) EMD Serono Inc., 1 Technology Place, Rockland, MA 02370, USA;(3) Merck Serono S.A, Chemin des Mines 9, 1202 Geneva, Switzerland;(4) ZymoGenetics Inc, 1201 Eastlake Avenue, East Seattle, Washington 98102-3702, USA;(5) Case Western Reserve University, 2040 Adelbert Rd, Cleveland, OH 44106-7060, USA |
| Abstract: | IntroductionAtacicept is a soluble, fully human, recombinant fusion protein that inhibits B cell-stimulating factors APRIL (a proliferation-inducing ligand) and BLyS (B-lymphocyte stimulator). The APRIL- LN study aimed to evaluate the efficacy and safety of atacicept in patients with active lupus nephritis (LN), receiving newly initiated corticosteroids (CS) and mycophenolate mofetil (MMF). |
| Keywords: | atacicept clinical trial immunoglobulin lupus nephritis mycophenolate mofetil nephrotic-range proteinuria |
| 本文献已被 SpringerLink 等数据库收录！ | |